Hypoglycemic Effects of Fermented Red Ginseng in Subject With Impaired Fasting Glucose or Type 2 Diabetes

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01826409

Enrollment

Registered

2013-04-08

Start date

2008-03-31

Completion date

Unknown

Last updated

2013-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired Glucose or Type 2 Diabetes

Brief summary

This study was conducted to investigate the effects of daily supplementation of fermented red ginseng (FRG) on glycemic status in subjects with impaired fasting glucose (IFG) or type 2 diabetes.

Detailed description

This study was a 4 weeks, randomized, double-blind, placebo-controlled trial. Forty-two subjects with IFG or type 2 diabetes were randomly allocated to 2 groups to consume placebo or FRG three times per day for 4 weeks. Fasting and postprandial glucose profiles during meal tolerance test were assessed before and after the intervention.

Interventions

DIETARY_SUPPLEMENTFermented Red Ginseng

Fermented red ginseng 2.7g/day for 4 weeks

DIETARY_SUPPLEMENTPlacebo

Placebo 2.7g/day for 4 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Age 20-75 years with fasting glucose 100\ 140 mg/dL at least two of the following

Exclusion criteria

* Lipid metabolic disorder * Acute or chronic inflammatory disease * Taking medication of corticosteroid within 4 weeks of the study * Cardiovascular disease (arrhythmia, heart failure, myocardial infarction or patient with pacemaker) * Allergic or hypersensitive to any of the ingredients in the test products * Participation in other clinical trials within 2 months * Abnormal hepatic liver function or renal disease (acute/chronic renal failure or nephrotic syndrome) * Taking medication of lipid phosphates within 3 months of the study etc,

Design outcomes

Primary

Measure	Time frame	Description
Glucose profiles during meal tolerance test	4 weeks	Fasting and postprandial glucose profiles during meal tolerance test were assessed before(baseline) and after the intervention

Secondary

Measure	Time frame	Description
Change in lipid profiles	4 weeks	Change in lipid profiles were assessed before(baseline) and after the intervention

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026